The burden of severe cases of Influenza disease: the Friuli Venezia Giulia Region experience.


Journal

Journal of preventive medicine and hygiene
ISSN: 2421-4248
Titre abrégé: J Prev Med Hyg
Pays: Italy
ID NLM: 9214440

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 06 06 2019
accepted: 31 07 2019
entrez: 26 10 2019
pubmed: 28 10 2019
medline: 3 4 2020
Statut: epublish

Résumé

Influenza is a matter of serious concern for clinicians, in both outpatient and in-hospital settings. Worldwide, the 2017-18 epidemic proved to be the most severe since 2003-04. We report a real-world experience regarding the management of patients with influenza admitted to a large teaching hospital in the Friuli Venezia Giulia region during the 2017-2018 influenza season. We also provide a practical guide for the management of hospitalized influenza patients. A retrospective observational analysis was conducted among all influenza patients requiring admission to our center during the 2017-18 season. Overall, 29 patients were admitted to the University Hospital of Udine during the 2017-18 season with a diagnosis of influenza. B virus was responsible for the majority of cases. More than 65.5% of the subjects presented with a complication. We estimated that 41.4% of the patients admitted were affected by a "severe form". All these cases required admission to the Intensive Care Unit, with 27.6% and 10.3% needing Orotracheal Intubation and Extracorporeal Membrane Oxygenation, respectively. The fatality rate was 24.1%. Notably, only 9 subjects in our cohort had been vaccinated. Based on the experience acquired during the past season, we propose a practical guide to the management of influenza cases in everyday hospital practice. The cornerstones of the management of all hospitalized influenza patients are the rapid identification and treatment of severe forms. Timely and strict adherence to contact and respiratory precautions are also fundamental to reducing the risk of intra-hospital outbreaks. Despite improvements in antiviral therapies and supportive measures, influenza-related morbidity and mortality remain high. In our opinion, a universal vaccination program is the only safe and effective method of filling the gap.

Identifiants

pubmed: 31650049
doi: 10.15167/2421-4248/jpmh2019.60.3.1314
pmc: PMC6797893
doi:

Substances chimiques

Antiviral Agents 0
Influenza Vaccines 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

E163-E170

Informations de copyright

©2019 Pacini Editore SRL, Pisa, Italy.

Références

Clin Infect Dis. 2002 Aug 15;35(4):370-7
pubmed: 12145718
Vaccine. 2017 Feb 22;35(8):1104-1109
pubmed: 28131392
Euro Surveill. 2018 Mar;23(9):
pubmed: 29510782
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Clin Infect Dis. 2018 Jun 18;67(1):8-17
pubmed: 29324996
Hum Vaccin Immunother. 2018 Mar 4;14(3):540-549
pubmed: 28708957
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Epidemiol Infect. 2013 Sep;141(9):1807-15
pubmed: 23098364
Influenza Other Respir Viruses. 2017 Sep;11(5):372-393
pubmed: 28745014
Influenza Other Respir Viruses. 2008 Nov;2(6):211-9
pubmed: 19453397
Euro Surveill. 2013 Feb 28;18(9):null
pubmed: 23470023
Vaccine. 2012 Nov 6;30(48):6794-801
pubmed: 23000125
Clin Infect Dis. 2019 Mar 5;68(6):e1-e47
pubmed: 30566567
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
JAMA Cardiol. 2019 Apr 1;4(4):363-369
pubmed: 30916717
Euro Surveill. 2018 Mar;23(13):
pubmed: 29616611
Vaccine. 2017 Jan 5;35(2):212-221
pubmed: 27939013
Hum Vaccin Immunother. 2017 Feb;13(2):379-384
pubmed: 27924687
Hum Vaccin Immunother. 2013 Mar;9(3):561-7
pubmed: 23292210
Cell Host Microbe. 2015 Mar 11;17(3):295-300
pubmed: 25766291
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):634-642
pubmed: 29879098
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637

Auteurs

M Bassetti (M)

Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

M Peghin (M)

Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

T Gallo (T)

Department of Prevention, Local Health Unit 4 Medio Friuli, Udine, Italy.

C Pipan (C)

Microbiology Unit, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

P D'Agaro (P)

Department of Medical, Surgical and Health Sciences, University of Trieste, Italy.

A Sartor (A)

Microbiology Unit, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

T Bove (T)

Anesthesiology and Intensive Care Medicine, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

R Cocconi (R)

SOC Direzione Medica di Presidio, Azienda Sanitaria Universitaria Integrata di Udine, Italy.

E Graziano (E)

Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

N Castaldo (N)

Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH